Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have received an average rating of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $106.08.
Several research firms have commented on ITCI. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Tuesday. They issued a “hold” rating for the company. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Finally, Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th.
View Our Latest Analysis on Intra-Cellular Therapies
Institutional Investors Weigh In On Intra-Cellular Therapies
Intra-Cellular Therapies Stock Performance
Shares of NASDAQ ITCI opened at $131.24 on Wednesday. Intra-Cellular Therapies has a 52-week low of $63.30 and a 52-week high of $131.36. The stock has a market cap of $13.95 billion, a P/E ratio of -150.85 and a beta of 0.72. The firm has a 50 day moving average price of $116.44 and a 200 day moving average price of $92.52.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Analysts predict that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Further Reading
- Five stocks we like better than Intra-Cellular Therapies
- Growth Stocks: What They Are, What They Are Not
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Tesla Stock: Finding a Bottom May Take Time
- What is the S&P 500 and How It is Distinct from Other Indexes
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.